Casopis lekaru ceskych · 1995
[Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hrebícek J, Skottová N, Chmela Z, Hrbková M
Аннотация
BACKGROUND: Duolip forte (ethophyllinclofibrate) is a lipid lowering drug, the effect of which was not yet adequately verified in our conditions, namely from the point of its effect on various types of hyperlipoproteinaemias.
METHOD AND RESULTS: The therapy was applied on 45 patients with combined hyperlipidaemia, 25 men and 20 women, mean age 53.8 years (age range 41-65). About one half of patients were treated for hypertension, almost one quart of them manifested ischemic heart disease, 13% had a history of myocardial infarction and the same percentage suffered from associated diabetes type 2. Duolip forte was administered perorally in a dose of 500 mg once daily for 12-16 weeks to the patients who had complied with the prescribed diet (weight loss, improvement of lipid levels) during three-month preliminary period, but did not reach desirable parameters. After the therapy, the whole group studied manifested a significant decrease of total cholesterol (-10.8%), LDL-cholesterol (-13%), triglycerides (-40.8%) and free fatty acids (-20.6%), while the increase of HDL-cholesterol and its fractions was not significant. In hyperlipoproteinaemias of IIa type (n = 15), only a significant decrease of LDL-cholesterol appeared, in hyperlipoproteinaemias of IIb type (n = 15), a significant decrease was evidenced only in triglycerides (-33.9%). In hyperlipoproteineaemias of IV type (n = 15), a significant decrease was observed in triglycerides (-50.3%), while HDL-2 cholesterol values increased (+32.3%). A slight decrease of uric acid level and of body mass index observed in all groups was statistically not significant, as well as a slight increase of glycaemia and changes of serum transaminases. No unwanted side effects of Duolip were found.
CONCLUSIONS: Ethophyllinclofibrate has proved as effective namely at hypertriglyceridemic primary hyperlipidaemias. Besides decreasing triglycerides, it increases significantly HDL-2 cholesterol. A convenient dosage, small lithogenic effect and minimum of side effects make it a drug of choice for some groups of elderly high-risk patients.
METHOD AND RESULTS: The therapy was applied on 45 patients with combined hyperlipidaemia, 25 men and 20 women, mean age 53.8 years (age range 41-65). About one half of patients were treated for hypertension, almost one quart of them manifested ischemic heart disease, 13% had a history of myocardial infarction and the same percentage suffered from associated diabetes type 2. Duolip forte was administered perorally in a dose of 500 mg once daily for 12-16 weeks to the patients who had complied with the prescribed diet (weight loss, improvement of lipid levels) during three-month preliminary period, but did not reach desirable parameters. After the therapy, the whole group studied manifested a significant decrease of total cholesterol (-10.8%), LDL-cholesterol (-13%), triglycerides (-40.8%) and free fatty acids (-20.6%), while the increase of HDL-cholesterol and its fractions was not significant. In hyperlipoproteinaemias of IIa type (n = 15), only a significant decrease of LDL-cholesterol appeared, in hyperlipoproteinaemias of IIb type (n = 15), a significant decrease was evidenced only in triglycerides (-33.9%). In hyperlipoproteineaemias of IV type (n = 15), a significant decrease was observed in triglycerides (-50.3%), while HDL-2 cholesterol values increased (+32.3%). A slight decrease of uric acid level and of body mass index observed in all groups was statistically not significant, as well as a slight increase of glycaemia and changes of serum transaminases. No unwanted side effects of Duolip were found.
CONCLUSIONS: Ethophyllinclofibrate has proved as effective namely at hypertriglyceridemic primary hyperlipidaemias. Besides decreasing triglycerides, it increases significantly HDL-2 cholesterol. A convenient dosage, small lithogenic effect and minimum of side effects make it a drug of choice for some groups of elderly high-risk patients.